At the time of this writing, Wuhan Neurophth Biotechnology is also recruiting for a phase 1/2/3 clinical trial of an ND4 gene therapy for LHON patients expected to conclude in 2027. This evidence concerns the gene MT-ND4 and Leber hereditary optic neuropathy.